RT Journal Article
SR Electronic
T1 Complex trait associations in rare diseases and impacts on Mendelian variant interpretation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.10.24301111
DO 10.1101/2024.01.10.24301111
A1 Smail, Craig
A1 Ge, Bing
A1 Keever-Keigher, Marissa R.
A1 Schwendinger-Schreck, Carl
A1 Cheung, Warren
A1 Johnston, Jeffrey J.
A1 Barrett, Cassandra
A1 Genomic Answers for Kids Consortium
A1 Feldman, Keith
A1 Cohen, Ana S.A.
A1 Farrow, Emily G.
A1 Thiffault, Isabelle
A1 Grundberg, Elin
A1 Pastinen, Tomi
YR 2024
UL http://medrxiv.org/content/early/2024/01/11/2024.01.10.24301111.abstract
AB Emerging evidence implicates common genetic variation – aggregated into polygenic scores (PGS) – impacting the onset and phenotypic presentation of rare diseases. In this study, we quantified individual polygenic liability for 1,151 previously published PGS in a cohort of 2,374 probands enrolled in the Genomic Answers for Kids (GA4K) rare disease study, revealing widespread associations between rare disease phenotypes and PGSs for common complex diseases and traits, blood protein levels, and brain and other organ morphological measurements. We observed increased polygenic burden in probands with variants of unknown significance (VUS) compared to unaffected carrier parents. We further observed an enrichment in overlap between diagnostic and candidate rare disease genes and large-effect PGS genes. Overall, our study supports and expands on previous findings of complex trait associations in rare disease phenotypes and provides a framework for identifying novel candidate rare disease genes and in understanding variable penetrance of candidate Mendelian disease variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCS is supported by NIH grants R35GM146966 and R21HG012422. The work of GA4K was made possible in part by generous gifts to Children's Mercy Research Institute at Children's Mercy Kansas City.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Children's Mercy Institutional Review Board/IRB (Study 11120514). Informed written consent was obtained from all participants prior to study inclusion.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes